| Literature DB >> 29038277 |
George L Drusano1, Michael L Corrado2, Gino Girardi3, Evelyn J Ellis-Grosse4, Richard G Wunderink5, Helen Donnelly5, Kenneth V Leeper6, Mona Brown6, Tasnova Malek6, Robert Duncan Hite7, Michelle Ferrari7, Danijela Djureinovic7, Marin H Kollef8, Lisa Mayfield8, Ann Doyle8, Jean Chastre9, Alain Combes9, Thomas J Walsh10, Krisztina Dorizas10, Hassan Alnuaimat11, Brooks Edward Morgan11, Jordi Rello12, Cristopher A Mazo12, Ronald N Jones13, Robert K Flamm13, Leah Woosley13, Paul G Ambrose14, Sujata Bhavnani14, Christopher M Rubino14, Catharine C Bulik14, Arnold Louie15, Michael Vicchiarelli15, Colleen Berman15.
Abstract
Ventilator-associated bacterial pneumonia (VABP) is a difficult therapeutic problem. Considerable controversy exists regarding the optimal chemotherapy for this entity. The recent guidelines of the Infectious Diseases Society of America and the American Thoracic Society recommend a 7-day therapeutic course for VABP based on the balance of no negative impact on all-cause mortality, less resistance emergence, and fewer antibiotic treatment days, counterbalanced with a higher relapse rate for patients whose pathogen is a nonfermenter. The bacterial burden causing an infection has a substantial impact on treatment outcome and resistance selection. We describe the baseline bronchoalveolar lavage (BAL) fluid burden of organisms in suspected VABP patients screened for inclusion in a clinical trial. We measured the urea concentrations in plasma and BAL fluid to provide an index of the dilution of the bacterial and drug concentrations in the lung epithelial lining fluid introduced by the BAL procedure. We were then able to calculate the true bacterial burden as the diluted colony count times the dilution factor. The median dilution factor was 28.7, with the interquartile range (IQR) being 11.9 to 53.2. Median dilution factor-corrected colony counts were 6.18 log10(CFU/ml) [IQR, 5.43 to 6.46 log10(CFU/ml)]. In a subset of patients, repeat BAL on day 5 showed a good stability of the dilution factor. We previously showed that large bacterial burdens reduce or stop bacterial killing by granulocytes. (This study has been registered at ClinicalTrials.gov under registration no. NCT01570192.).Entities:
Keywords: bacterial burden; bronchoalveolar lavage; ventilator-associated bacterial pneumonia
Mesh:
Substances:
Year: 2017 PMID: 29038277 PMCID: PMC5740323 DOI: 10.1128/AAC.01323-17
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191